Nisa Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.3M Sell
19,771
-1,191
-6% -$912K 0.06% 200
2025
Q4
$16.2M Buy
20,962
+950
+5% +$645K 0.05% 199
2025
Q3
$11.3M Sell
20,012
-739
-4% -$418K 0.04% 250
2025
Q2
$10.9M Sell
20,751
-26,595
-56% -$14.8M 0.05% 248
2025
Q1
$30M Sell
47,346
-1,510
-3% -$1.04M 0.15% 120
2024
Q4
$34.8M Buy
48,856
+19,114
+64% +$16M 0.14% 117
2024
Q3
$31.3M Buy
29,742
+7,506
+34% +$8.35M 0.19% 114
2024
Q2
$23.4M Buy
22,236
+788
+4% +$764K 0.15% 146
2024
Q1
$20.6M Sell
21,448
-795
-4% -$756K 0.13% 164
2023
Q4
$19.5M Sell
22,243
-390
-2% -$321K 0.14% 159
2023
Q3
$18.6M Sell
22,633
-1,082
-5% -$850K 0.14% 162
2023
Q2
$17M Sell
23,715
-597
-2% -$460K 0.13% 176
2023
Q1
$20M Buy
24,312
+3,913
+19% +$2.95M 0.16% 153
2022
Q4
$14.7M Sell
20,399
-590
-3% -$435K 0.12% 206
2022
Q3
$14.5M Sell
20,989
-2,032
-9% -$1.28M 0.12% 178
2022
Q2
$13.6M Buy
23,021
+2,494
+12% +$1.62M 0.12% 190
2022
Q1
$14.3M Hold
20,527
0.1% 200
2021
Q4
$12.5M Sell
20,527
-2,315
-10% -$1.42M 0.09% 224
2021
Q3
$13.8K Buy
22,842
+400
+2% +$248K 0.08% 216
2021
Q2
$12.5K Buy
22,442
+2,248
+11% +$1.14M 0.08% 234
2021
Q1
$9.55K Sell
20,194
-1,135
-5% -$553K 0.06% 278
2020
Q4
$10.3M Sell
21,329
-1,840
-8% -$993K 0.07% 274
2020
Q3
$13M Sell
23,169
-1,697
-7% -$1.03M 0.1% 203
2020
Q2
$15.5M Sell
24,866
-5,191
-17% -$2.95M 0.14% 154
2020
Q1
$14.7M Buy
30,057
+3,060
+11% +$1.26M 0.16% 139
2019
Q4
$10.1M Buy
26,997
+5,597
+26% +$1.88M 0.09% 223
2019
Q3
$5.94M Sell
21,400
-576
-3% -$170K 0.05% 338
2019
Q2
$6.88M Buy
21,976
+1,995
+10% +$664K 0.07% 291
2019
Q1
$8.21M Sell
19,981
-1,400
-7% -$577K 0.08% 240
2018
Q4
$7.99M Sell
21,381
-261
-1% -$95.5K 0.09% 221
2018
Q3
$8.74M Buy
21,642
+3,098
+17% +$1.18M 0.08% 240
2018
Q2
$6.4M Sell
18,544
-8,577
-32% -$2.68M 0.07% 290
2018
Q1
$9.27M Buy
27,121
+5,286
+24% +$1.84M 0.1% 212
2017
Q4
$8.21M Sell
21,835
-1,641
-7% -$665K 0.08% 237
2017
Q3
$10.5M Buy
23,476
+2,371
+11% +$1.13M 0.12% 195
2017
Q2
$10.2M Sell
21,105
-100
-0.5% -$43.8K 0.12% 186
2017
Q1
$8.22M Buy
21,205
+7,159
+51% +$2.65M 0.1% 226
2016
Q4
$5.16M Sell
14,046
-1,394
-9% -$530K 0.06% 306
2016
Q3
$6.21M Buy
15,440
+1,500
+11% +$602K 0.08% 260
2016
Q2
$4.87M Sell
13,940
-900
-6% -$347K 0.07% 319
2016
Q1
$5.35M Buy
14,840
+620
+4% +$255K 0.08% 276
2015
Q4
$7.72M Buy
14,220
+400
+3% +$217K 0.11% 193
2015
Q3
$6.55M Buy
13,820
+2,820
+26% +$1.51M 0.1% 202
2015
Q2
$5.61M Sell
11,000
-200
-2% -$97.6K 0.08% 260
2015
Q1
$5.06M Buy
11,200
+200
+2% +$84.8K 0.07% 290
2014
Q4
$4.51M Sell
11,000
-200
-2% -$78.7K 0.06% 317
2014
Q3
$4.04M Buy
11,200
+700
+7% +$235K 0.06% 323
2014
Q2
$2.97M Sell
10,500
-400
-4% -$119K 0.04% 433
2014
Q1
$3.27M Buy
10,900
+900
+9% +$277K 0.05% 387
2013
Q4
$2.75M Buy
10,000
+300
+3% +$86.3K 0.04% 439
2013
Q3
$3.04M Sell
9,700
-3,900
-29% -$1.03M 0.05% 396
2013
Q2
$3.06M Buy
+13,600
New +$3.17M 0.05% 374

Other funds holding REGN

Nisa Investment Advisors's REGN Position: Q1 2026 in Review

Nisa Investment Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 5.7% in Q1 2026, selling an estimated $912K and leaving 19,771 shares worth $15.3M. The position accounts for 0.06% of the portfolio, ranked #200.

Nisa Investment Advisors first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $34.8M in Q4 2024. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Nisa Investment Advisors held 19,771 shares of Regeneron Pharmaceuticals worth $15.3M as of Q1 2026.
  • Nisa Investment Advisors sold 1,191 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $912K.
  • Regeneron Pharmaceuticals made up 0.06% of Nisa Investment Advisors's portfolio in Q1 2026, its #200 holding.
  • Nisa Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Nisa Investment Advisors's Regeneron Pharmaceuticals position peaked at $34.8M in Q4 2024.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.